Find out the highlights of the EPNS Academy on (Auto)Immune disorders in child neurology held on the final day of the EPNS Congress 2019. We reflect on the key players driving the immense progress made in this field utilising genetic therapy and look ahead to what we might expect in 2021. You can find daily roundups of the most interesting lectures and symposia below:
Even more on gene therapy today – see the new data from the SPR1NT and STR1VE-EU studies in spinal muscular atrophy and a thought-provoking discussion of the ethical dilemmas associated with gene therapy trials. What are the adverse events seen with gene therapy and how will next generation sequencing change your medical practice?
The EPNS Congress 2019 is the place to be this week for all that is happening in paediatric neurology. We look ahead to the highlights in neuromuscular disorder research that the epgonline.org team will be reporting on.
The epgonline.org team were at the 13th European Paediatric Neurology Society (EPNS) Congress, that took place between the 17–21 September in Athens, Greece. Seminars, scientific sessions, industry-sponsored symposia and poster sessions covered topics such as neonatal neurology, neurogenetics and neuromuscular disease. A highlight was therapeutic developments in neuromuscular diseases, primarily spinal muscular atrophy (SMA) but also Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS).
The focus for EPNS this year is in the area of genetics, environment, progression and transition within paediatric neurology and rare diseases. Our daily Congress highlights report on the exciting line-up of local and global experts exchanging clinical and scientific knowledge on the latest developments, innovations and emerging challenges within paediatric neurology.